The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | AlloCARs and CAR-NK cells in myeloma
Chimeric antigen receptor (CAR) T-cells require a long and extensive production process, and are not readily available to patients as off-the-shelf treatments. A solution to this could be the development of allogenic-CAR T-cells (alloCARs) or CAR-natural killer (CAR-NK) cells. In this video, Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, discusses the latest updates on the use of alloCARs and CAR-NK cells in the treatment of multiple myeloma, and outlines the next steps in this field. Prof. Einsele reports that data from clinical trials suggests that these treatment methods could be successful, although there is not yet enough research to consider these as viable options. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
